(Q53851252)

21 May 2018

title

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). (English)

1 reference

21 May 2018

author name string

B Gazzard

series ordinal

1

1 reference

21 May 2018

BHIVA Writing Committee

series ordinal

2

1 reference

21 May 2018

publication date

1 July 2005

1 reference

21 May 2018

published in

HIV Medicine

1 reference

21 May 2018

volume

6 Suppl 2

1 reference

21 May 2018

page(s)

1-61

1 reference

21 May 2018

Time trends in primary HIV-1 drug resistance among recently infected persons

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Ethnic differences in stage of presentation of adults newly diagnosed with HIV-1 infection in south London

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Sex differences in nevirapine rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Sex differences in HAART-associated dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Legal and political considerations of clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

AIDS across Europe, 1994-98: the EuroSIDA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Virologic and regimen termination surrogate end points in AIDS clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Interventions to enhance patient adherence to medication prescriptions: scientific review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Drug resistance in patients experiencing early virological failure under a triple combination including indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

High levels of adherence do not prevent accumulation of HIV drug resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Will we ever know when to treat HIV infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

CD4 cell counts in adults with newly diagnosed HIV infection: results of surveillance in England and Wales, 1990-1998. CD4 Surveillance Scheme Advisory Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Virologic and immunologic values allowing safe deferral of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group prot

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

A prospective trial of structured treatment interruptions in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

HIV RNA in plasma rebounds within days during structured treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Therapeutic drug monitoring as a tool in treating HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Liver toxicity caused by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Mitochondrial toxicity hypothesis for lipoatrophy: a refutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Lipodystrophy in patients naive to HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

The metabolic effects of lopinavir/ritonavir in HIV-negative men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Regulated transport of the glucose transporter GLUT4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Lactic acidosis complicating the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Mitochondrial toxic effects and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Report of three cases of hyperlactacidemiae/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Impact of drug resistance mutations on virologic response to salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Control of HIV despite the Discontinuation of Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Risk of new AIDS diseases in people on triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Immune control of HIV-1 after early treatment of acute infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Antiretroviral Concentrations in Untimed Plasma Samples Predict Therapy Outcome in a Population with Advanced Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

21 January 2018

Letters to the Editor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.0311B.X

10.1111/J.1468-1293.2005.0311B.X

21 January 2018

Identifiers

DOI

1 reference

21 May 2018

1 reference

21 May 2018